8月13日，国家药品监督管理局药品审评中心（CDE）官网显示，复宏汉霖（02696.HK）和亿胜生物（01061.HK）联合递交了贝伐珠单抗眼内注射液（HLX04-O）的上市申请。Insight数据库显示，这是第2个在国内报上市的贝伐珠单抗眼科制剂。HLX04-O是复宏汉霖利用基因工程技术构建的一款重组抗VEGF人源化单克隆抗体注射液，能够特异性结合VEGF，阻断VEGF与内皮细胞上的受体Flt1...
Source Link8月13日，国家药品监督管理局药品审评中心（CDE）官网显示，复宏汉霖（02696.HK）和亿胜生物（01061.HK）联合递交了贝伐珠单抗眼内注射液（HLX04-O）的上市申请。Insight数据库显示，这是第2个在国内报上市的贝伐珠单抗眼科制剂。HLX04-O是复宏汉霖利用基因工程技术构建的一款重组抗VEGF人源化单克隆抗体注射液，能够特异性结合VEGF，阻断VEGF与内皮细胞上的受体Flt1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.